EMEA-003459-PIP01-23

Published 10 hours ago• 1 minute read

Active Substance: recombinant adeno-associated virus Olig001 containing human aspartoacylase cDNA
Therapeutic area: Congenital, familial and genetic disorders
Decision number: P/0214/2024
PIP number: EMEA-003459-PIP01-23
Pharmaceutical form(s): Solution for injection
Condition(s) / indication(s): Treatment of Canavan disease
Route(s) of administration: Intracerebral use
Contact for public enquiries
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Recommended Articles